MedTrace Logo

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

NCT05531708 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-03-01

No results posted yet for this study

Summary

This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of novel Mesothelin CAR-T in patients with Mesothelin-positive advanced refractory solid tumors.

Conditions

  • Mesothelin-positive Advanced Refractory Solid Tumors

Interventions

BIOLOGICAL

Anti-mesothelin CAR-T cells

D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.

DRUG

Fludarabine

D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.

DRUG

Cyclophosphamide

D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.

Sponsors & Collaborators

  • UTC Therapeutics Inc.

    collaborator INDUSTRY

  • Shanghai Pudong Hospital

    lead OTHER

Principal Investigators

  • Zhiguo Long · Shanghai Pudong Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-02
Primary Completion
2025-04-30
Completion
2026-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05531708 on ClinicalTrials.gov